Neuralstem Inc. (CUR) Receives Notice of Allowance for Patent Applications
Today, Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth." These patents cover three new compounds and include structure and method claims for inducing neurogenesis and the in-vitro and in-vivo growth of new neurons. Neuralstem's first neurogenic patented compound is currently in a FDA-approved Phase I safety trial in major depressive disorder. Phase IA of the trial, which will use healthy volunteers, is scheduled to be completed in August. The Phase IB safety trial, which will use depressed patients, will commence this fall. "These patents cover…